PIM1 and acute myeloid leukemia: To determine the effects of gilteritinib and Pim inhibitor cotreatment on expression of c-Myc, relative to Mcl-1, Ba/F3-ITD, MV4-11, and MOLM-14 cells and blasts from a patient with AML with FLT3-ITD were treated with gilteritinib and/or AZD1208, or DMSO control, and Ba/F3-ITD, MV4-11, and MOLM-14 cells were also treated with gilteritinib and/or TP-3654, or DMSO control.